Known targets — ChEMBL curated mechanism
ABL1BRAFDDR2EPHA2FGFR1FGFR2FLT1FLT4FRKKDRKITMAPK11NTRK1PDGFRAPDGFRBRAF1RETTEK
The experimentally established mechanism targets of Regorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.98 |
| ▸ | BRAF known ✓ | P15056 | 7/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.98 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.98 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.98 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.98 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.98 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.98 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 0.98 |
| ▸ | MAPK11 known ✓ | Q15759 | 2/20 | 0.98 |
| ▸ | DDR2 known ✓ | Q16832 | 2/20 | 0.98 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.82 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.82 |
| ▸ | FRK known ✓ | P42685 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regorafenib SCHEMBL2555101 | 1.00 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29351376 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29349808 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL432230 | 0.99 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29496390 | 0.98 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2554008 | 0.98 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2552684 | 0.96 | RAF1 (0.93) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL30433607 | 0.93 | RAF1 (0.89) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL5086313 | 0.92 | RAF1 (0.87) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL22627130 | 0.91 | RAF1 (0.85) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| EP-4460314-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| EP-4444870-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118382694-A | Methods and compositions for generating human erythroid progenitors | 特雷尔赫德生物系统股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-118217246-A | Multi-stage nano preparation loaded with collagenase and anti-fibrosis drug and application thereof | 锦州医科大学 | 2024-06-21 | — | — | CN | claimed |
| CN-117917399-A | Preparation method of regorafenib crystal form I | 重庆药友制药有限责任公司 | 2024-04-23 | — | — | CN | claimed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2023107477-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-06-15 | — | — | WO | claimed |
| US-20230174938-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2023-06-08 | — | — | US | claimed |
| CN-115894356-A | Crystal forms of regorafenib sulfate and hydrochloride and preparation method thereof | 北京百奥药业有限责任公司 | 2023-04-04 | — | — | CN | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| CN-115894356-A | Crystal forms of regorafenib sulfate and hydrochloride and preparation method thereof | 北京百奥药业有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115894356-A | Crystal forms of regorafenib sulfate and hydrochloride and preparation method thereof | 北京百奥药业有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2023-01-12 | — | — | US | disclosed |
| EP-4010081-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114315710-A | Method for preparing or purifying regorafenib | 江苏豪森药业集团有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CTTN, SRC, FYN | RAF1 129/4885BRAF 109/4885KDR 504/4885 |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | DCX, SLC10A2, CHAT | RAF1 2333/4885BRAF 2375/4885KDR 4667/4885 |
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | RAF1 369/4885BRAF 910/4885KDR 1920/4885 |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | CDK9, KRAS, BRD9 | RAF1 147/4885BRAF 201/4885KDR 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.